(2R,3S)-2-Allyl-N⁴-[(S)-1-benzyl-2-oxo-2-(1H-pyrrol-2-yl)-ethyl]-N¹-hydroxy-3-isobutyl-succinamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3S)-2-Allyl-N⁴-[(S)-1-benzyl-2-oxo-2-(1H-pyrrol-2-yl)-ethyl]-N¹-hydroxy-3-isobutyl-succinamide
• 英文别名: (2S,3R)-N-hydroxy-3-(2-methylpropyl)-N'-[(2S)-1-oxo-3-phenyl-1-(1H-pyrrol-2-yl)propan-2-yl]-2-prop-2-enylbutanediamide
• 化学式: C₂₄H₃₁N₃O₄
• 分子量: 425.528
• InChiKey: JMYNELQJPYBCPZ-ZVDOUQERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  111
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-O-tert-butyl 4-O-(2,3,4,5,6-pentafluorophenyl) (2S,3R)-3-(2-methylpropyl)-2-prop-2-enylbutanedioate 在 N-甲基吗啉 、 O-(叔丁基二甲基硅烷)羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (2R,3S)-2-Allyl-N⁴-[(S)-1-benzyl-2-oxo-2-(1H-pyrrol-2-yl)-ethyl]-N¹-hydroxy-3-isobutyl-succinamide
  参考文献：
  名称：

  Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors

  摘要：

  A series of succinyl hydroxamate MMP inhibitors were prepared incorporating an aryl amino ketone moiety in place of the more typical C-terminal amino acid amides. Compounds of the C-terminal ketone series displayed potent inhibition of MMPs. Several compounds of the series were shown to be orally bioavailable. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00597-6

文献信息

• Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors
  作者：George S. Sheppard、Alan S. Florjancic、Jamie R. Giesler、Lianhong Xu、Yan Guo、Steven K. Davidsen、Patrick A. Marcotte、Ildiko Elmore、Daniel H. Albert、Terrance J. Magoc、Jennifer J. Bouska、Carole L. Goodfellow、Douglas W. Morgan、James B. Summers

  DOI：10.1016/s0960-894x(98)00597-6

  日期：1998.11

  A series of succinyl hydroxamate MMP inhibitors were prepared incorporating an aryl amino ketone moiety in place of the more typical C-terminal amino acid amides. Compounds of the C-terminal ketone series displayed potent inhibition of MMPs. Several compounds of the series were shown to be orally bioavailable. (C) 1998 Elsevier Science Ltd. All rights reserved.